CSF-1/CSF-1R inhibitors have been identified as therapeutic targets for a variety of malignant tumors, such as glioma, hepatocellular carcinoma, breast cancer, lung cancer and pancreatic cancer (27), and have broad application prospects in tumor immunotherapy (Table 1). Here, CSF1 is linked to pancreatic neoplasm.